How Brenner was paid
$2.1M in total for fiscal Year 2026, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Options | Incentive | Other | Total |
|---|---|---|---|---|---|
| Dr. Martin B. BrennerChief Executive Officer and Chief Scientific Officer | $580,000 | $1,224,254 | $319,000 | $13,680 | $2,136,934 |
| Felipe DuranChief Financial Officer | $415,500 | $464,373 | $182,820 | $18,605 | $1,081,298 |
| Marc BanjakChief Legal Officer | $400,000 | $373,275 | $176,000 | $17,181 | $966,456 |
What changed and why
- $2.14M$2.14 million: CEO total compensation in fiscal 2026, up from $1.51 million in fiscal 2025.
- $1.22M$1.22 million: CEO option awards represented the largest component of fiscal 2026 compensation.
- $319K$319,000: CEO non-equity incentive compensation based on achievement of corporate objectives.
- 40%40%: CFO bonus target under his amended employment agreement.
- 150%150%: Cap on annual cash incentive payments relative to target.
- 92%92%: Say-on-pay votes cast in favor at the 2025 annual meeting.
Other iBio proxy statements
- 2025 proxy statement
Dr. Martin B. Brenner paid $1.5M (+19% on the year).
Filed Oct 06, 2025
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.